Concerta

Janssen's once-daily 12-hour OROS extended-release methylphenidate — same drug as Ritalin, smarter delivery (osmotic pump → ascending plasma curve). A-tier evidence for ADHD; A-tier for acute cognition in users without ADHD (same as IR methylphenidate). For Dylan: SKIP-FOR-NOW MEDIUM — no ADHD diagnosis, and the 12-hour duration that makes Concerta superior for diagnosed adults is the exact wrong fit for a 20yo late chronotype already fighting a 2-3 AM bedtime. Modafinil is the better lane.

Drug: Concerta contains the same racemic methylphenidate as Ritalin. The dextro-threo enantiomer (d-MPH, the molecule sold isolated as Focalin) does ~90% of the work. Mechanism is identical to Ritalin: blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), raising synaptic dopamine and norepinephrine in prefrontal cortex (focus, executive function) and dorsal striatum (motor/attention gating). It does NOT cause vesicular release like amphetamines — just blocks reuptake of what's already being released. This is why the subjective "stim" is generally cleaner and less euphoric than amphetamines.

Delivery — this is where Concerta is different:

Concerta is a tri-layer OROS (Osmotic-controlled Release Oral delivery System) tablet, originally developed by ALZA (now part of Janssen / Johnson & Johnson). The tablet has three internal compartments inside a semipermeable membrane:

1. Outer overcoat (~22% of dose): Immediate-release methylphenidate dissolves in the stomach within ~1 hour, providing the initial loading dose. This is what gets you to therapeutic concentration fast.
2. Two drug layers (~78% of dose): Inside the semipermeable shell, separated from a third compartment by a moveable barrier.
3. Osmotic push layer: An expanding polymer that swells as water is drawn through the semipermeable membrane.

A single laser-drilled hole at the top of the tablet is the only exit. As the osmotic layer swells, it pushes the drug layers out through the hole at a controlled rate. The tablet is mechanically rigid — chewing or crushing it does NOT release the full dose at once (this is the abuse-resistance feature).

Result — the ascending plasma curve:

Unlike a typical sustained-release matrix (which produces a flat plateau followed by decline), Concerta is engineered to produce an ascending plasma profile that mimics 3× IR doses spaced throughout the day. Within 1 hour, plasma MPH reaches an initial plateau (from the overcoat), then gradually rises over the next 5-9 hours as the osmotic pump pushes increasing amounts of drug. Peak (Cmax) typically occurs 6-10 hours post-dose, in the afternoon for a morning dose.

Why ascending instead of flat? Acute methylphenidate tolerance develops within hours — a flat plasma curve causes diminishing subjective effect over the day (this is why patients on flat SR formulations report "wearing off" mid-afternoon). The ascending curve compensates for acute tolerance development by raising drug exposure throughout the day, maintaining clinical effect across school/work hours.

Pharmacokinetics:

• Oral bioavailability ~22-30% (low, but consistent — first-pass metabolism dominates)
• Tmax ~6-10 hours (vs. ~1-2 hours for IR Ritalin)
• Half-life ~3.5 hours (parent compound) — but the OROS delivery extends the effective duration to ~12 hours
• Metabolism: Primarily by carboxylesterase 1 (CES1) — NOT CYP-mediated. This is mechanistically important: methylphenidate has far fewer CYP-mediated drug interactions than amphetamines or modafinil. Major metabolite: ritalinic acid (inactive). CYP2D6 is NOT involved (Markowitz 2000).
• Excretion: Renal, primarily as ritalinic acid. ~60-86% recovered in urine.